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Abstracts
Background: To evaluate the efficacy of cetuximab combined with modified FOLFIRI (mFOLFIRI) as a second-line
treatment in metastatic gastric cancer patients and to identify potential biomarkers of clinical outcomes.
Methods: All 61 patients received an initial intravenous (IV) dose of cetuximab (400 mg/m2) and weekly doses (250 mg/
m2) thereafter, starting on day 1. On day 2 of each 14-day period, patients received IV irinotecan (180 mg/m2), leucovorin
(200 mg/m2), and an IV bolus dose of 5-FU (400 mg/m2) followed by a continuous infusion of 5-FU (2400 mg/m2) for
46 h. The primary endpoint was time-to-progression (TTP).
Results: The response rate (RR) was 33.3% among 54 evaluable patients. In the intention-to-treat analysis, median TTP
was 4.6 months (95% confidential interval [CI]: 3.6-5.6 months) and median overall survival (OS) was 8.6 months (95% CI: 7.
3-9.9 months). In univariate analyses, plasma vascular endothelial growth factor (VEGF) levels were correlated with clinical
outcome. In patients with low (≤12.6 pg/ml) and high (>12.6 pg/ml) baseline plasma VEGF levels, RR values were 55.0%
and 5.3%, respectively (P = 0.001); median TTP values were 6.9 months and 2.8 months, respectively (P = 0.0005); and
median OS values were 12 months and 5 months, respectively (P <0.0001). None of these patients exhibited KRAS, BRAF,
or PIK3CA mutations.
Conclusions: Combination therapy comprising cetuximab and mFOLFIRI was well tolerated and active as a second-line
treatment for patients with metastatic gastric cancer. Patients with low baseline plasma VEGF levels were associated with
better clinical outcomes.
Trial registration: ClinicalTrials.gov. NCT00699881. Registered 17 June 2008 (retrospectively registered)
Keywords: Cetuximab, FOLFIRI, Gastric cancer, Biomarker
* Correspondence: fudanlijin@163.com
†Equal contributors
1Department of Medical Oncology, Fudan University Shanghai Cancer
Center, 270 Dong-An Road, Shanghai 200032, China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Liu et al. BMC Cancer  (2017) 17:188 
DOI 10.1186/s12885-017-3174-z
Background
Metastatic gastric cancer (MGC), an incurable disease
with a poor prognosis, is marked by a short median overall
survival (OS) time. Chemotherapy comprising fluoropyri-
midine and platinum (combined with trastuzumab in
HER-2 positive patients) has been considered as standard
therapeutic regimen in the first-line setting [1–3].
Almost all of the MGC patients experienced disease
progression afte first-line treatment. Salvage chemother-
apy (SLC), as second-line treatment, has been shown to
significantly improve survival when added to best support-
ive care (BSC). A large Korean study randomized patients
with MGC with one or two prior chemotherapy regimens
(70% one prior therapy) to SLC (either docetaxel or irino-
tecan) plus BSC or BSC alone, and found that median OS
was prolonged in the SLC arm (5.3 vs. 3.8 months), with
no median OS difference between docetaxel and irinote-
can [4]. A Japanese phase III study (WJOG4007) com-
pared treatment with paclitaxel and irinotecan in patients
with MGC refractory to treatment with fluoropyrimidine
plus platinum. This study reported no significant differ-
ence between paclitaxel and irinotecan for OS [5]. Thus,
both irinotecan and taxanes are reasonable second-line
treatment options for MGC. The RAINBOW study
showed ramucirumab (a VEGFR-2 antagonist) could in-
crease median OS when combined with paclitaxel in
second-line treatment for patients with MGC [6].
However, the efficacy of second-line chemotherapy for
MGC is still very limited. It’s urgently needed to improve
the prognosis of these patients. The combination of cetuxi-
mab (an EGFR antagonist) and irinotecan has been widely
used in the second or third-line treatment of metastatic
colorectal cancer (mCRC) patients [7, 8]. The BOND study
found that cetuximab may circumvent irinotecan resistance
in patients with irinotecan refractory tumors [9]. At the
time of our study design, some phase II trials assessed
cetuximab combined with chemotherapy in the first-line or
second-line treatment of gastric cancer [10, 11]. Since irino-
tecan is one of the major drugs used in the second-line
treatment for MGC, and enlightened by the striking syner-
gistic effects from the irinotecan-cetuximab combination in
mCRC, we presumed that irinotecan-cetuximab combin-
ation may improve the efficacy in second-line treatment for
MGC. Then we did some preclinical studies to explore
whether cetuximab could enhance the activities of irinote-
can on gastric cancer cell lines, and the results showed sig-
nificant potentiation of antiproliferative, apoptosis and G2/
M phase arrest effects in response to the addition of cetuxi-
mab to irinotecan in GC cell lines via the downregulation
of the EGFR pathway upregulated by irinotecan [12].
Therefore, this phase II clinical trial (NCT00699881) was
designed to evaluate the safety and efficacy of cetuximab
combined with modified FOLFIRI (mFOLFIRI) in patients
with MGC who failed to first-line chemotherapy. Plasma
protein levels of VEGF and EGF, gene mutations of KRAS,
BRAF and PIK3CA, and expression of P27, phosphorylated
EGFR and AKT in tumor tissues were also investigated for
their potential roles as biomarkers of clinical outcomes.
Methods
Patient eligibility
This open-label, single-arm, multicenter, phase II study in-
cluded patients who met the following eligibility criteria:
aged between 18 and 70 years; histologically confirmed
metastatic or locally advanced gastric adenocarcinoma with
at least one measurable lesion in a non-irradiated area; one
prior chemotherapy regimen (except adjuvant chemother-
apy); Eastern Cooperative Oncology Group (ECOG) per-
formance status (PS) of 0 or 1; adequate organ function
(bone marrow function: neutrophil count [ANC] ≥2.0 ×
109/L, platelet count [PLT] ≥80 × 109/L; liver function:
serum bilirubin and serum transaminase levels ≤1.5 ×ULN
[upper limit of normal]; renal function: serum creatin-
ine ≤1.0 × ULN). The following criteria were applied
for patient exclusion from the study: patients who re-
ceived cetuximab or irinotecan as a first-line chemother-
apy; pregnant or breast-feeding or were of child-bearing
potential without using adequate contraception; had any
other current or prior malignancy (with the exception of
excised cervical carcinoma in situ or squamous cell skin
carcinoma treated by surgery only); had central nervous
system metastases; had severe or uncontrolled medical
conditions (e.g., impaired heart and lung function, dia-
betes, active infections, or liver disease).
This study was approved by the Fudan University
Shanghai Cancer Center Institutional Review Board and
conducted according to the Declaration of Helsinki. All
patients provided written informed consent prior to par-
ticipation in this study.
Treatment and assessment
Cetuximab was administered at an initial dose of
400 mg/m2, followed by weekly infusions (250 mg/m2).
On day 2 of each 14-day period, patients received IV iri-
notecan (180 mg/m2) and LV 200 mg/m2 and then 5-FU
(400 mg/m2) IV bolus followed by a continuous infusion
of 5-FU (2400 mg/m2) for 46 h. Treatment was contin-
ued until development of progressive disease (PD), oc-
currence of unacceptable toxic effects, or withdrawal of
patient consent. Dose reductions and/or administration
delays were applied in cases of febrile neutropenia, grade
4 myelosuppression, or grade 3/4 non-hematological
toxic effects. In cases where chemotherapy was discon-
tinued due to its toxicity, patients were allowed to con-
tinue with cetuximab. A special dose reduction scheme
was specified for skin-related toxic effects.
Response evaluation was performed according to the
Response Evaluation Criteria in Solid Tumors (RECIST)
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every eight weeks during treatment period and every
3 months after treatment was discontinued. Complete
responses (CR) or partial responses (PR) were confirmed
with CT scans performed at least 4 weeks apart. Adverse
events (AEs) including rash were evaluated according to
the National Cancer Institute Common Terminology
Criteria for Adverse Events (version 3.0).
Biomarker analyses
Plasma EGF and VEGF level analysis
Venous blood for cytokine assessment was drawn into
an ethylenediaminetetraacetic acid (EDTA) anticoagulant
tube immediately prior to the first drug infusion. Each
venous blood sample was immediately centrifuged for
10 min at 4,000 rpm and the plasma was stored at -80 °
C for subsequent assay of vascular endothelial growth
factor (VEGF) and endothelial growth factor (EGF)
levels by enzyme-linked immunosorbent assay (ELISA)
according to the instructions provided by the manufacturer
(Invitrogen, US). All samples were assayed in duplicate.
Mutation analysis
Mutation analysis of KRAS, BRAF, and PIK3CA genes
was performed by extraction of genomic DNA from
formalin-fixed, paraffin-embedded tissue slides or sec-
tions using the QIAamp DNA Mini Kit (Qiagen,
Germany). DNA was amplified using oligonucleotide
primers specific for human KRAS (exons 12 and 13),
BRAF (V600E) and PIK3CA (exons 9 and 20) genes and
then screened with pyrosequencing.
Protein expression analysis by immunohistochemical
staining
Immunohistochemical (IHC) staining of tumor samples
was carried out to assess the expression of phosphory-
lated EGF receptor (pEGFR), and EGFR downstream
molecules, such as phosphorylated AKT (pAKT), P27
and m-TOR. PTEN expression was also analysed, which
located in upstream of PI3K/AKT. Positive staining was
defined as staining above background level in ≥10% of
cancer cells.
Statistical considerations
The primary endpoint was time-to-progression (TTP).
This study was designed to test the hypothesis that a
median TTP value of 4.0 months (H1) obtained in this
study is significantly different from the value of
2.5 months (H0), which represents the median TTP of
FOLFIRI as the second-line treatment for gastric cancer.
Sample size was determined following Gehan’s two-stage
phase II optimal trial design. Fifteen patients were en-
rolled in the first stage. If TTP ≥ 4 months was observed
in five or more patients, the study proceeded to the sec-
ond stage where an additional 31 patients were enrolled.
Assuming a 20% drop-out rate, a total of 55 patients
were required for this study.
The secondary endpoints of the study included the RR,
OS, AEs, and potential biomarkers. Survival curves were
generated using the Kaplan-Meier method and compari-
sons of TTP and OS between groups were performed by
log-rank tests. Safety analysis was performed for the safety
population, which consisted of all patients who received at
least one dose of cetuximab. As an exploratory endpoint,
activating mutations of the KRAS, BRAF, and PIK3CA
genes, expression of pEGFR, pAKT, P27, mTOR and
PTEN in tumor samples, plasma protein level of VEGF,
EGF, and their association with efficacy and prognosis
were also analyzed. A receiver operating characteristic
(ROC) curve analysis was used for selection of a cut-off
point for the ligand level, which was defined as the ligand
level with the highest sensitivity and specificity for the re-
sponse. Statistical analysis of the correlation between bio-
marker status and RR was carried out using a Pearson’s χ2
test or Fisher’s Exact test.
TTP and OS were analyzed in the intent-to-treat
(ITT) population. TTP was calculated from the day of
the first infusion to the date of documented disease pro-
gression or last contact. Patients who had not progressed
at the time of the final analysis were censored at the date
of their last tumor assessment. OS was calculated from
the day of the first infusion to death. Patients alive at the
final survival analysis were censored using the last con-
tact date. Statistical analyses were performed using SPSS
software (version 12.0; SPSS, Chicago, IL, USA).
Results
Patient disposition
Between May 2008 and November 2009, 61 patients
with metastatic gastric cancer were enrolled into the
study from three participating hospitals. All 61 patients
were evaluated for safety and survival, and 54 were as-
sessable for response. Seven patients were not assessable
for response due to discontinuation without tumor as-
sessment within the first cycle of treatment as a result of
obstructive jaundice (n = 1), febrile neutropenia (n = 3),
and intestinal obstruction (n = 3). At the time of data
cut-off at the end of December 2010, all patients had
discontinued treatment.
Patient characteristics
Of the 61 patients enrolled, 56% were male (n = 34) and
44% were female (n = 27), with a median age of 52 years
(range 26-69). All treated patients had an ECOG PS of 0 or
1 (PS 0: 28%; PS 1: 72%). The primary tumor was located at
the gastroesophageal junction (GEJ) in 23% of the patients
and at other parts of the stomach in 77% of the patients.
Prior surgery of the primary tumor had been performed in
66% of the patients. All patients presented with metastatic
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disease. The predominant metastatic sites were abdominal
lymph nodes (56%), liver (44%), and lung (18%). First-line
chemotherapy regimens used in the study population were
as follows: 56% of the patients received ECF (epirubicin,
cisplatin, 5-FU) and its variants (fluorouracil replaced by
capecitabine and/or cisplatin by oxaliplatin), 21% received
fluoropyrimidine plus oxaliplatin, 21% received fluoropyri-
midine plus docetaxel or paclitaxel, and 2% received cape-
citabine monotherapy (Table 1).
Efficacy
The best overall responses are listed in Table 2. Fifty four
patients were evaluable for response including one
complete remission and 17 partial responses, resulting in a
RR of 33.3% (18/54) patients (95% CI, 20.7% to 45.9%).
Stable disease (SD) was observed in 50% (27/54) of patients
(95% CI 43.3%–56.7%) and PD in 16.7% (9/54) of patients
(95% CI 6.8%–26.6%). The DCR (CR + PR + SD) was 83.3%
(95% CI 73.4%–93.2%).
The median follow-up time was 16 months. At the time
of analysis, 97% (59/61) of enrolled patients presented with
progressive disease and 15% (9/61) remained alive. In the
ITT population, median TTP was 4.6 months (95% CI, 3.6
to 5.6 months; Fig. 1a) and the median OS was 8.6 months
(95% CI, 7.3-9.9 months; Fig. 1b). In an analysis of TTP
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5-FU/capecitabine + oxaliplatin 13 21
ECF/EOF/EOX 34 56
5-FU plus TXT/PTX 13 21
Capecitabine 1 2
Abbreviations: ECOG Eastern Cooperative Oncology Group, PS performance
status, 5-FU 5- fluorouracil, ECF epirubicin, cisplatin, 5-FU, EOF epirubicin,
oxaliplatin, 5-FU, EOX epirubicin, capecitabine, oxaliplatin, TXT, docetaxel,
PTX, paclitaxel
Table 2 Overall responses
Number Percentage (%)
Assessable patients 54 100





DCR (CR + PR + SD) 45 83.3
Abbreviations: CR complete response, PR partial response, SD stable disease,
PD progressive disease, DCR disease control rate
Fig. 1 Kaplan–Meier estimates of (a) time-to-progression (TTP) and (b)
overall survival (OS) among patients with metastatic gastric cancer
treated with cetuximab, irinotecan, folinic acid and 5-fluorouracil (FOLFIRI)
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and OS in relation to tumor response, patients with a CR
or PR had longer TTP times (median: 8.6 months vs.
4.0 months, P = 0.006) and OS times (median: 13.7 months
vs. 7.0 months, P = 0.0016) compared with patients with
SD or PD.
Safety
The median number of infusions of cetuximab was 18.0
(1–48), while the median number of cycles of FOLFIRI
was 8.0 (0–19). All 61 patients were evaluated for toxicity.
Treatment was generally well tolerated and the major tox-
icity observed was hematological. Grades 3/4 neutropenia,
anemia and thrombocytopenia occurred in 52.5%, 29.5%,
and 8.2% of patients, respectively. Febrile neutropenia was
recorded in 13.1% of patients. Overall, non-hematological
toxicities were moderate and severe episodes were rare.
The most common grades 3/4 non-hematological toxic-
ities were nausea (8.2%), vomiting (6.6%), asthenia (4.9%),
infection (4.9%), stomatitis (1.6%), and diarrhea (6.6%).
Cetuximab-related grade 3 hypersensivity reaction was re-
ported in one patient (1.6%). All grades of acne-like rash
occurred in 70.8% (51/61) of patients and grades 3/4
toxicities were observed in 9.8% (6/61) of patients
(Table 3). No other serious adverse events were observed.
Biomarker analyses
Plasma protein level analysis
A ROC curve analysis showed that the cut-off point for the
VEGF level was 12.6 pg/ml. In patients with low (≤12.6 pg/
ml) and high (>12.6 pg/ml) baseline plasma VEGF levels,
RR values were 55.0 and 5.3%, respectively (P = 0.001);
median TTP values were 6.9 months and 2.8 months,
respectively (P = 0.0005); and median OS values were
12 months and 5 months, respectively (P <0.0001) (Fig. 2).
Baseline plasma EGF levels did not correlate with any of
the clinical outcomes (Table 4).
Mutational analysis
Forty DNA samples were evaluable for gene mutation
analysis. None of the patients in this study exhibited
KRAS, BRAF or PIK3CA mutations.
Protein expression analysis
Fifty-one tumor samples were available for protein expres-
sion analysis. pEGFR expression was detected in 27.5% (14/
51) of patients. In pEGFR-negative and pEGFR-positive
patients, RR were 32.4 and 28.6%, respectively (P = 0.791);
median TTP were 5.3 months and 4.3 months, respectively
(P = 0.503); and median OS were 7.8 months and
9.1 months, respectively (P = 0.520). pAKT expression was
detected in 47.1% (24/51) of patients (47.1%). In pAKT-
negative and pEGFR-positive patients, RR were 29.6%
and 33.3%, respectively (P = 0.776); median TTP were
5.2 months and 4.0 months, respectively (P = 0.497);
and median OS were 8.1 months and 9.1 months, respect-
ively (P = 0.394). We have also detected protein expression
of P27 and mTOR in the tumors, which located in EGFR
downstream signally pathways and protein expression of
PTEN, which located in upstream of PI3K/AKT. However,
no correlations were identified among P27, m-TOR and
PTEN expression and RR, median TTP or OS (Table 4).
Discussion
This phase II study was conducted to assess the efficacy
and safety of cetuximab combined with mFOLFIRI as a
second-line therapy in patients with metastatic gastric
cancer following the failure of first-line chemotherapy.
The median TTP observed in this study was 4.6 months,
which exceeded the pre-specified criteria of 4 months,
with a RR of 33.3%, a DCR of 83.3% and a median OS of
8.6 months. Treatment was generally well tolerated and
the predominant grade 3/4 treatment-related toxic ef-
fects were neutropenia (52.5%), anemia (29.5%), and
thrombocytopenia (8.2%). It seems that the median TTP
observed in our study was better than in previously re-
ported studies. In WJOG4007 study, median PFS was
3.6 months in the paclitaxel group and 2.3 months in
the irinotecan group for the second-line treatment of
MGC [5]. Moreover, the median TTP in our study was
similar with that of ramucirumab plus paclitaxel in
RAINBOW study (median PFS was 4.4 months), which
was the only successfully developed target drug com-
bined with chemotherapy in second-line setting with the
best effects [6]. So the preliminary results of our study
are exciting.
Table 3 Grade 3 or 4 Adverse Events (National Cancer Institute
Common Toxicity Criteria, Version 3.0)
Number (n = 61) Percentage (%)
Hematological toxicity
Neutropenia 32 52.5










Intestinal obstruction 4 6.6
Elevated aminotransferase 1 1.6
Allergic reaction 1 1.6
Rash 6 9.8
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Fig. 2 Kaplan–Meier curves of time-to-progression (a) and overall survival (b) according to serum protein level of vascular endothelial growth factor
(VEGF). P-value by log-rank test
Table 4 Univariate analyses of biomarker and treatment outcomes
RR (%) P-value Median TTP (mo) P-value Median OS (mo) P-value
Tumor expression (IHC)
pEGFR negative 32.4 0.79 5.3 0.50 7.8 0.52
positive 28.6 4.3 9.1
pAKT negative 29.6 0.78 5.2 0.50 8.1 0.39
positive 33.3 4.0 9.1
P27 negative 23.1 0.22 4.9 0.25 7.3 0.33
positive 40.9 5.6 9.2
positive 34.3 5.1 9.2
PTEN negative 31.1 0.56 4.4 0.28 8.2 0.39
positive 35.2 4.9 9.0
Serum protein level (ELISA) (pg/ml)
VEGF ≤12.6 55.0 0.001 6.9 0.0005 12 <0.0001
>12.6 5.3 2.8 5
EGF ≤0.70 31.8 1.00 4.7 0.61 8.3 0.58
>0.70 29.4 4.0 8.9
RR response rate, TTP time-to-progression, OS overall survival, mo months, IHC immunohistochemistry, PEGFR phosphorylated epidermal growth factor receptor,
PAKT phosphorylated AKT, ELISA enzyme-linked immunosorbent assay, VEGF vascular endothelial growth factor, EGF epidermal growth factor, mTOR mammalian
target of rapamycin, PTEN phosphatase and tensin homolog deleted on chromosome ten. P < 0.05 are significant and marked in bold
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Two randomised phase 3 trials assessed anti-EGFR
antibodies in the first-line setting of MGC. In EXPAND
trial, the patients were randomly assigned to receive
chemotherapy (capecitabine plus cisplatin) or chemo-
therapy combined with cetuximab. The results showed
mPFS was not prolonged with the addition of cetuximab
to chemotherapy (5.6 months for chemotherapy alone vs
4.4 months for chemotherapy plus cetuximab) [13]. In
REAL3 trial, the patients were randomly assigned to re-
ceive chemotherapy (epirubicin, oxaliplatin, and capecit-
abine) or chemotherapy combined with panitumumab.
The results showed the addition of panitumumab to
chemotherapy was associated with inferior OS (median
OS: 11.3 months vs 8.8 months for chemotherapy alone
and panitumumab plus chemotherapy, respectively) [14].
However, the failure of these trials may due to several
reasons. Firstly, evidence in the setting of colorectal cancer
suggests that oxaliplatin and capecitabine may be subopti-
mum partners of anti-EGFR antibodies. Preclinical studies
suggest that greater synergy might exist between cetuxi-
mab and irinotecan than with oxaliplatin. Oxaliplatin was
found to activate SRC in colon cancer cells by ROS-
dependent pathway, which leads to the activation of EGFR
signaling and decreasing of the effects of cetuximab [15].
In clinical studies, cetuximab could increase the effects of
irinotecan contained regimen for patients with mCRC.
However, cetuximab combined with oxaliplatin had incon-
sistent results in mCRC. The COIN study showed addition
of cetuximab to FOLFOX or XELOX could not improve
PFS and OS even in patients with KRAS wild-type un-
treated mCRC. However, subgroup analysis showed cetux-
imab could not improve PFS of patients treated with
oxaliplatin plus capecitabine, while improved PFS with
cetuximab was noted in individuals treated with FOLFOX
[16]. The NORDIC VII study showed the effect of cetuxi-
mab was disappointing with regard to PFS and OS when
added to FLOX in which oxaliplatin combined with bolus
5Fu [17]. The CALGB/SWOG 80405 study showed that
the effect of cetuximab combined with FOLFOX was com-
parable with that of cetuximab combined with FOLFIRI
[18]. The TAILOR study showed that cetuximab plus
FOLFOX significantly improved PFS in the first-line treat-
ment of patients with RAS wild-type mCRC compared
with FOLFOX alone. These studies suggested that the ef-
fect of cetuximab combined with oxaliplatin contained
regimen might depend on the usage of fluoropyrimidine:
cetuximab might improve the effect of oxaliplatin when
combined with civ 5-Fu, but couldn’t when combined with
bolus 5-Fu or capecitabine. EGFR antagonists were com-
bined with capecitabine and platinum in both EXPAND
and REAL3 trials, the failure of which may attribute to the
drug interactions.
Secondly, cetuximab exerts best effect when it’s used
in second or third-line setting of mCRC, which has
poorer prognosis. It’s harder to improve the outcome of
first-line treatment because of the better efficacy com-
pared with the salvage treatment. In EPIC study, cetuxi-
mab added to irinotecan significantly improved PFS
(median, 4.0 v 2.6 months; P = .0001) for the second-line
therapy of mCRC [7]. However, in CRYSTAL study, the
improvement of median PFS with cetuximab was less
conspicuous (8.9 months with cetuximab plus FOLFIRI
and 8.0 months with FOLFIRI alone) for the first-line
therapy of mCRC. The similar situation occurred with
bevacizumab [19]. In E3200 study, the addition of beva-
cizumab to chemotherapy resulted in a statistically sig-
nificant improvement in OS for patients with previously
treated mCRC [20]. However, in No16966 trial, the
addition of bevacizumab to chemotherapy could not
prolong OS for the first-line treatment of mCRC [21].
Furthermore, in AVAGAST trial, the addition of bevaci-
zumab to chemotherapy didn’t improve the OS for the
first-line of MGC [22]. However, in RAINBOW study,
the addition of ramucirumab, which has similar mechan-
ism of action with bevacizumab, could increase median
OS in second-line treatment for patients with MGC [6].
So, the failure of EGFR antagonists in the first-line set-
ting of MGC in both EXPAND and REAL3 trials could
not conclude that cetuximab was useless when com-
bined with other drugs or in the second-line setting. In
our study, preliminary exciting effects were obtained
when cetuximab combined with irinotecan and 5-Fu civ
in second-line setting, which deserves to be confirmed
in further randomized controlled clinical trials.
Moreover, gastric cancer may comprise a group of het-
erogeneous diseases that differ in the expression of cell-
signaling molecules and have varying degrees of metaplasia,
and therapy in a molecularly selected population may result
in better outcomes. Therefore, potential biomarkers of
cetuximab therapy in combination with FOLFIRI as a
second-line treatment in MGC patients were selected and
analyzed based on their roles in EGFR-mediated signaling
in our study. Mutations in KRAS, BRAF and PIK3CA genes
were not identified. In accordance with previous reports,
the frequency of KRAS activating mutations was found to
be low in GC patients [23]. The efficacy of cetuximab is
limited to patients with KRAS wild-type tumors in mCRC
[24]. However, unlike in mCRC where KRAS mutation fre-
quencies are approximately 35% to 45%, KRAS was not
identified as a suitable predictive marker of cetuximab effi-
cacy in GC [25, 26]. Protein expression analyses (pEGFR
and pAKT expression) also had negative results in our
study.
All grades of acne-like rash occurred in 70.8% of patients
and grades 3/4 toxicities were observed in 9.8% of the
patients, and this side-effect did not correlate with the
clinical outcomes in this study. Although the associations
of the presence and severity of cetuximab-related skin rash
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with clinical outcome have been reported in mCRC
patients [27], but the role of cetuximab-related skin rash
in clinical outcome remains inconclusive in AGC. In the
FOLCETUX study, RR values were higher in patients with
skin rash grade ≥2 compared with grade <2 (53% vs. 33%),
but the difference was not statistically significant [11].
Similar results were reported by another study [28].
In gastric cancer, it has been reported that VEGF expres-
sion was associated with tumor aggressiveness and poor
prognosis [29, 30]. Juttner S et al found that elevated circu-
lating VEGF levels could promote tumor aggression and
shorten survival in patients with gastric cancer [31]. Jung
YD et al found that the inhibition of VEGFR-2 could de-
crease tumor growth and vascularization in animal models
of gastric cancer [32]. Ramucirumab, a human IgG1 mono-
clonal antibody VEGFR-2 antagonist, has been proven to
prolong OS in the second-line treatment of MGC either as
monodrug or combined with paclitaxel. These results sug-
gested VEGF and VEGFR-2-mediated signalling and angio-
genesis contribute to the pathogenesis of gastric cancer.
Vincenzi and colleagues revealed the reduction of serum
VEGF levels could predict the efficacy of treatment with
cetuximab plus irinotecan in heavily pretreated mCRC pa-
tients [33]. Therefore in this study we also annalyzed the
value of VEGF as a potential marker, and our data showed
patients with low baseline plasma VEGF levels experienced
a more favorable outcomes. In patients with baseline
plasma VEGF levels less than12.6 pg/ml, OS time was pro-
longed by up to 12 months compared with 5 months in pa-
tients with VEGF levels higher than 12.6 pg/ml (P <0.0001),
so were the TTP (6.9 months vs. 2.8 months, respectively,
P = 0.0005) and the RR (55.0% vs. 5.3%).
Our findings are consistent with recent studies sug-
gesting that EGFR signaling pathways are involved in
tumor angiogenesis, especially through the upregulation
of VEGF. The phosphorylation of EGFR signalling could
lead to the activation of PI3K/AKT and RAS/RAF/MEK/
MAPK pathways, which could induce tumor angiogen-
esis. EGFR antagonists could inhibit angiogenic growth
factor production (VEGF) and tumor-induced angiogen-
esis [34]. Khong et al found that EGFR phosphorylation
activates the MAP kinase signalling and promotes HIF
stabilisation in CRC. HIF activation and EGF-mediated
signalling could induce the activation of angiogenic
genes, such as ANGPTL4, EFNA3, TGFβ1 and VEGF
[35]. It is hypothesized that elevated VEGF, which pro-
motes tumor angiogenesis, induces acquired resistance
to EGFR treatment. Grimminger et al found that pre-
treatment intratumoral VEGF mRNA expression levels
are predictive markers of pathologic response to neoad-
juvant cetuximab based chemoradiation in locally ad-
vanced rectal cancer [36]. Preclinical studies point out
that inhibition of EGFR by cetuximab could downregu-
late the expression of VEGF [37, 38]. Viloria-Petit A et
al reported that A431 cells with overexpression of VEGF
were resistant to anti-EGFR antibodies and A431 xeno-
grafts with acquired resistance to anti-EGFR antibodies
showed higher levels of VEGF [39]. Bianco R et al also
found that GEO colon cancer cells with increased VEGF
expression were resistant to EGFR inhibitors and
VEGFR-1 tyrosine kinase inhibitor could reduce tumor
growth in animal models [40]. These observations sug-
gested that VEGF pathway plays an important role in
mediating tumor responses and drug resistance to anti-
EGFR therapies. The importance of VEGF pathway in
MGC has recently been magnified by the positive results
with Ramucurimab in MGC. However, the biomarker
analyses are exploratory in nature in our study.
Conclusions
In conclusion, our study showed cetuximab combined with
mFOLFIRI was well tolerated and preliminary encouraging
efficacy data were obtained in the second-line treatment of
MGC. Furthermore, biomarker analysis indicated that gas-
tric cancer patients with low baseline circulating VEGF
levels have better clinical outcomes. As our study is single
arm, the value of cetuximab in the second-line treatment
of MGC and the value of biomarker need to be confirmed
in further randomized controlled clinical trials.
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